The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients

The American Society of Clinical Oncology recommends that full weight-based doses of chemotherapy be used to treat obese patients with cancer. However, many oncologists limit the dose of chemotherapy based on ideal body weight or a maximum body surface area (BSA) of m2. The objective of our study is to determine how weight-based chemotherapy dosing affects toxicity, treatment delays, and laboratory values in a cohort of obese gynecologic cancer patients at our institution. We hypothesize that full weight-based dosing in obese patients does not increase adverse chemotherapy outcomes